CIM 101
Alternative Names: CIM-101Latest Information Update: 24 Oct 2023
At a glance
- Originator CiMaas
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 06 Oct 2023 Preclinical trials in Acute myeloid leukaemia in Netherlands (Parenteral) before October 2023 (CiMaas pipeline, October 2023)
- 06 Oct 2023 Pharmacodynamics data from a preclinical trial in acute myeloid leukaemia released by CiMaas (CiMaas website, October 2023)
- 06 Oct 2023 CiMaas plans a phase I/IIa trial for Acute myeloid leukaemia in Q4 2023 (CiMaas pipeline, October 2023)